Table 2.
OS HR by subtype relative to luminal A in the combined MONALEESA dataset.
| Ribociclib Arm | Placebo Arm | |||
|---|---|---|---|---|
| HRa (95% CI) | P value | HRa (95% CI) | P value | |
| Univariate analysis | ||||
| Luminal Ab | 1.00 (–) | – | 1.00 (–) | – |
| Luminal B | 1.22 (0.92–1.62) | 0.17 | 1.41 (1.06–1.87) | 0.018 |
| HER2E | 1.94 (1.42–2.65) | <0.0001 | 2.62 (1.81–3.79) | <0.0001 |
| Basal-like | 7.84 (4.43–13.88) | <0.0001 | 2.56 (1.37–4.76) | 0.0031 |
| Multivariable Cox analyses of prognostic variables c | ||||
| Luminal Ab | 1.00 (–) | – | 1.00 (–) | – |
| Luminal B | 1.16 (0.86–1.57) | 0.32 | 1.47 (1.08–2.00) | 0.014 |
| HER2E | 1.83 (1.33–2.52) | 0.00022 | 2.87 (1.93–4.26) | <0.0001 |
| Basal-like | 7.22 (3.81–13.70) | <0.0001 | 2.35 (1.20–4.57) | 0.012 |
Abbreviation: HER2E, human epidermal growth factor receptor 2–enriched.
aAdjusted HR for multivariate analyses.
bLuminal A is used as the reference group in this analysis; thus, 95% CIs and P values could not be calculated for the luminal A subgroup here.
cAdjusted HRs obtained from multivariable Cox model including age, prior chemotherapy, prior endocrine therapy, Eastern Cooperative Oncology Group performance status, visceral disease (presence of liver/lung metastases), bone-only metastases, histologic grade, number of metastatic sites, tumor type, and de novo metastatic disease.